Olivier Danos, Ph.D.

Olivier Danos, Ph.D.

EVP, Chief Scientific OfficeratRegenxbio· In proxies 2021–2024

Pay in FY2024-1% from the year before · Regenxbio stock -56.9% the same year

Olivier Danos, Ph.D. was paid $3.0M in FY2024 (Dec), down 1%. Regenxbio stock fell 56.9% that year.

Pay$100 in the stock at the end of FY20 → $17
Pay is from the Summary Compensation Table of each Regenxbio proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. RegenxbioPublic company · 5 yr
    • EVP, Chief Scientific Officer2021 – Present · 5 yrStock in role -85%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?